Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid-guided targeted therapy for locally advanced thyroid cancer
NCT06482086Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, lenvatinib, sorafenib, donafenib, everolimus in thyroid cancer, sponsored by West China Hospital of Sichuan University. Started Jun 2021; status: recruiting.
02
Drugs
anlotiniblenvatinibsorafenibdonafenibeverolimus
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT06482086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482086.